Biogen
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Biogen sits in the top decile of US sponsors by registered trial count (#109 of 15,742 sponsors by registered trial count).
Biogen: 334 sponsored US clinical trials, 21 recruiting.
Biogen sponsors 334 registered US clinical trials on ClinicalTrials.gov, 21 of them currently recruiting, and 237 completed. 84 of these trials are in Phase 3-4 (later-stage) and 198 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis, with 13 trials.
Top-decile sponsor footprint
Biogen ranks in the top decile of sponsors by registered trial count (#109 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
237 of 302 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
334 total, page 7 of 7
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
NCT00529438
Natalizumab Re-Initiation of Dosing
NCT00306592
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
NCT00345189
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
NCT00344786
A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis
NCT00288990
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
NCT00526812
Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis
NCT00292422
Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases
NCT00107861
Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL
NCT00319930
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors
NCT00105170
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
NCT00102024
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
NCT00083759
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
NCT00078611
Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT00103558
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT00099489
Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)
NCT00168714
Open-Label Natalizumab Safety Extension Study
NCT00276172
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
NCT00090038
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
NCT00168727
AVONEX® Combination Trial - "ACT"
NCT00112034
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
NCT00057343
Safety and Tolerability of Repeat Courses of IM Alefacept
NCT00233662
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma
NCT00048555
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
NCT00046488
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
NCT00599274
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
NCT00280956
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
NCT00031083
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
NCT00055536
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
NCT00055367
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
NCT00030966
Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma
NCT00575068
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
NCT00032799
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
NCT00027300
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
NCT00168740
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 135 |
| Phase 2 | 63 |
| Phase 3 | 71 |
| Phase 4 | 13 |
What is open in the Biogen pipeline
21 recruiting of 334 indexed (6% open); 237 completed (71%).
Phase mix: 84 late (III/IV) vs 198 early (I/II) (early-phase heavy).
Top condition: Multiple Sclerosis (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Biogen: open-pipeline peers nationwide
Peers matched on 334 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Biogen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 334 trials (± recruiting share)
- National Institute on Drug Abuse (NIDA) · 335 trials · 4% recruiting
- Genentech · 332 trials · 7% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Albert Einstein Healthcare Network · 6% recruiting · 48 trials
- Altimmune · 6% recruiting · 16 trials
- Bassett Healthcare · 6% recruiting · 16 trials
- Dynavax Technologies Corporation · 6% recruiting · 16 trials
Related
What to do with this Biogen page
334 registered trials is a research-attention snapshot, not an endorsement of Biogen or any single study.
- 21 of Biogen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Sclerosis is the condition Biogen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Biogen pipeline card: 334 registered trials from official public datasets.Report a data error.